We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current AREC market cap is 49M. The company's latest EPS is GBP -0.3024 and P/E is -5.24.
| Year End December 30 2022 | 2019 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 1.65M | 1.45M | 2.15M | 1.8M | 3.54M |
| Operating Income | -2.86M | -1.57M | -3.43M | -6.44M | -10.7M |
| Net Income | -2.44M | -1.28M | -2.75M | -6.17M | -9.26M |
| Year End December 30 2022 | 2019 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 5.45M | 4.31M | 4.28M | 20.92M | 21.77M |
| Total Liabilities | 1.24M | 1.1M | 3.51M | 2.37M | 4.31M |
| Total Equity | 4.22M | 3.21M | 774k | 18.55M | 17.46M |
| Year End December 30 2022 | 2019 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -2.51M | -268k | -1.86M | -5.45M | -10.78M |
| Investing | -64k | -14k | -49k | -68k | -7.99M |
| Financing | 5.32M | -77k | 1.77M | 20.93M | 5.16M |
| Market Cap | 49M |
| Price to Earnings Ratio | -5.24 |
| Price to Sales Ratio | 13.73 |
| Price to Cash Ratio | 10.19 |
| Price to Book Ratio | 2.78 |
| Dividend Yield | - |
| Shares Outstanding | 30.63M |
| Average Volume (1 week) | 53.08k |
| Average Volume (1 Month) | 28.97k |
| 52 Week Change | -37.25% |
| 52 Week High | 255.00 |
| 52 Week Low | 124.00 |
| Spread (Intraday) | 3 (1.88%) |
| Company Name | Arecor Therapeutics Plc |
| Address |
chesterford research park london CB10 1XL |
| Website | https://www.arecor.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
